TrialJournal of hematology & oncology2016

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.

Joel G Turner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.